research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
Search
for
Sort by
Research
30 / 1000+ results 
research Alopecia universalis following interferon alfa-2b and ribavirin treatment for hepatitis C.
A woman lost all her body hair after hepatitis C treatment, but it started to grow back a year after stopping the treatment.
research Cutaneous necrosis after injection of polyethylene glycol–modified interferon alfa
Some patients receiving pegylated interferon alfa injections developed skin necrosis, requiring treatment adjustments or discontinuation.
research Drug-induced postinfantile giant cell hepatitis
Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
research Reversible alopecia universalis secondary to PEG-interferon ??-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection
A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.
research Hepatitis C Treatment and Alopecia Totalis
Hepatitis C treatment may trigger complete hair loss, especially in those with a history of patchy hair loss, but hair usually grows back within a year.
research Cutaneous Reactions in Patients with Chronic Hepatitis C Treated with Peginterferon and Ribavirin
Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
research Reversible Alopecia Universalis During Treatment with PEG-Interferon and Ribavirin for Chronic Hepatitis C
Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.
research Bullous Lesions at Polyethylene Glycol Interferon-alpha-2a Inoculation Site in a Hepatitis C Virus-infected Subject
A patient developed a blister at the injection site after hepatitis C treatment.
research Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report
A man lost all his hair as a rare side effect after hepatitis C treatment.
research The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients
Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
research Advances in nucleoside monophosphate prodrugs as anti-HCV agents
New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.
research Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report
A man lost all his hair after stopping hepatitis C treatment and it didn't grow back.
research Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects
Manage side effects of hepatitis C treatment with dose changes and medications, which may improve patient adherence and treatment success.
research Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
A man lost all his hair permanently after hepatitis C treatment, a side effect not seen before.
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area
Skin problems like itching, dry skin, and hair loss are more common in hepatitis C patients after interferon treatment, but lichen planus is not linked to the infection.
research Drug Repositioning: New Opportunities for Older Drugs
Finding new uses for existing drugs is promising and can lead to safer, more effective medicines.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Skin diseases associated with hepatitis C virus: Facts and controversies
Hepatitis C virus can cause skin diseases and dermatologists play a crucial role in identifying these conditions.
research A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin
Interferon and ribavirin can cause serious skin reactions and other health issues.
research Off-label uses of retinoids in dermatology
Retinoids are effective for various skin conditions and hair loss but have serious side effects, so low doses are recommended.
research Alopecia Universalis Successfully Treated With Adalimumab
A woman with severe hair loss was successfully treated with the drug adalimumab.
research Dermatological manifestations associated with COVID‐19: A comprehensive review of the current knowledge
COVID-19 can cause various skin issues, including rashes and hair loss, which usually heal on their own and don't always indicate severe illness.
research Effect of interferon therapy on quality of life in patients with chronic hepatitis B
Interferon therapy improves quality of life for chronic hepatitis B patients.
research Chemically Induced Hair Loss/Alopecia
Some chemicals and drugs can cause hair loss, which usually grows back after stopping the treatment.
research Index
Chemotherapy can cause skin issues and hair loss, and this guide explains how to manage them.
research Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege
A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
research Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
A woman's hair loss during Hepatitis C treatment with PEG-INF-a-2a and Ribavirin was reversible after stopping the medication.
research A randomized controlled clinical trial of recombinant interferon α‐2b in the treatment of acute post‐transfusion hepatitis C: A preliminary report
Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.